
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics Inc. has demonstrated a robust financial position with cash and investments increasing to $16.6 million, supported by CPRIT advances and market activities, alongside compliance with Nasdaq listing standards. The company's CNSide Diagnostic platform is showing promising commercial readiness, with expected revenue growth from approximately $1 million in 2025 to $38 million by 2032, fueled by expanding licensing and user adoption in new states. Positive preliminary results from the ReSPECT-LM study highlight a 76% radiographic response rate and a promising mean overall survival of 9 months, suggesting strong potential for future product advancements in CNS cancer treatment.
Bears say
Plus Therapeutics Inc. reported a total operating loss of $4.5 million and a net loss of $4.4 million, indicating significant financial challenges. The company’s reliance on grant revenue, which stood at only $1.4 million, raises concerns about its ability to sustain operations without additional funding. Furthermore, the dilution from the recent equity raise has contributed to a downward adjustment in the price target, reflecting investor apprehension regarding the company's financial stability and future prospects.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares